110 related articles for article (PubMed ID: 309061)
21. [T-lymphocytes and their function in Hodgkin's disease].
Michlmayr G
Fortschr Med; 1978 Oct; 96(38):1928-32. PubMed ID: 308921
[TBL] [Abstract][Full Text] [Related]
22. Changes in peripheral blood lymphocytes and immune complexes in splenectomized patients: lack of correlation with residual splenic function.
Corazza GR; Zoli G; Massai G; Mulè P; Beltrandi E; Gasbarrini G
J Clin Lab Immunol; 1990 Jan; 31(1):33-8. PubMed ID: 1966982
[TBL] [Abstract][Full Text] [Related]
23. [Hodgkin disease--pathogenesis and therapy].
Wolf J; Diehl V
Ther Umsch; 1996 Feb; 53(2):140-6. PubMed ID: 8629264
[TBL] [Abstract][Full Text] [Related]
24. Differential recovery of circulating T cell subsets after nodal irradiation for Hodgkin's disease.
Haas GS; Halperin E; Doseretz D; Linggood R; Russell PS; Colvin R; Barrett L; Cosimi AB
J Immunol; 1984 Feb; 132(2):1026-30. PubMed ID: 6361130
[TBL] [Abstract][Full Text] [Related]
25. Second malignant tumours in childhood Hodgkin's disease.
Jenkin D; Greenberg M; Fitzgerald A
Med Pediatr Oncol; 1996 Jun; 26(6):373-9. PubMed ID: 8614372
[TBL] [Abstract][Full Text] [Related]
26. [Immune profile in patients with Hodgkin's disease in long-term remission after cytostatic chemotherapy].
Nagel GA; Pietra CD; Hartmann D; Rosenthal M; Albrecht R; Obrist R; Obrecht P
Schweiz Med Wochenschr; 1979 Jan; 109(2):45-51. PubMed ID: 311514
[TBL] [Abstract][Full Text] [Related]
27. [Level of circulating immune complexes in lymphogranulomatosis patients as a criterion of the status and prognosis of the disease].
Savina NP
Ter Arkh; 1986; 58(9):60-4. PubMed ID: 3787494
[TBL] [Abstract][Full Text] [Related]
28. [E-RFC (T cells) and Ig-positive cells (B cells) in the peripheral blood of patients with lymphogranulomatosis and possible immunocorrection with levamisole].
Markova TP; Danilova NV
Ter Arkh; 1985; 57(7):15-8. PubMed ID: 3876611
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of IgE in malignant lymphogranulomatosis.
Powiertowska-Rezmer M; Rechowicz K; Rostkowska J; Snigurowicz J
Arch Immunol Ther Exp (Warsz); 1977; 25(1):101-6. PubMed ID: 301733
[TBL] [Abstract][Full Text] [Related]
30. [Cellular immune response and concentrations of serum immunoglobulins in patients with Hodgkin's disease (author's transl)].
Stefanits K; Kuhn E; Ambrus M; Csere T
Strahlentherapie; 1979 May; 155(5):335-40. PubMed ID: 442117
[TBL] [Abstract][Full Text] [Related]
31. [Changes in concentrations of IgM, IgA and IgM immune globulins after megavolt therapy with the large-field technic in patients with Hodgkin's disease].
Krüsmann W; Slanina J; Boser F; Löhr GW
Strahlenther Onkol; 1988 Jun; 164(6):323-9. PubMed ID: 3133799
[TBL] [Abstract][Full Text] [Related]
32. Serum immunoglobulin levels in splenectomized Hodgkin patients and in subjects following post-traumatic splenectomy.
Douer D; Chaimoff C; Pick AI; Pinkhas J
Oncology; 1981; 38(3):165-7. PubMed ID: 7207953
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the risk of solid tumor following Hodgkin's disease.
Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
[TBL] [Abstract][Full Text] [Related]
34. Immunologic impairment after long-term remission in splenectomized patients with Hodgkin's disease.
Loven D; Pick AI; Weiss H; Duczyminer-Kahana M; Lurie H
Acta Oncol; 1991; 30(6):763-5. PubMed ID: 1958399
[No Abstract] [Full Text] [Related]
35. The effect of thymic substances on T circulating cells of patients treated for Hodgkin's disease.
Chisesi T; Capnist G; Rancan L; Pellizzari G; Vespignani M
J Biol Regul Homeost Agents; 1988; 2(4):193-8. PubMed ID: 3074627
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
[TBL] [Abstract][Full Text] [Related]
37. Cellular and serological changes in the peripheral blood of splenectomized and spleen autotransplanted mice.
Sipka S; Bráth E; Tóth FF; Aleksza M; Kulcsár A; Fábián A; Baráth S; Balogh P; Sipka S; Furka I; Mikó I
Transpl Immunol; 2006 Aug; 16(2):99-104. PubMed ID: 16860712
[TBL] [Abstract][Full Text] [Related]
38. Circulating lymphoid cells in Hodgkin's disease.
Fairley GH
Natl Cancer Inst Monogr; 1973 May; 36():95-8. PubMed ID: 4270378
[No Abstract] [Full Text] [Related]
39. The influence of splenectomy, radiotherapy and chemotherapy on the immune response in Hodgkin's disease.
Van Rijswijk RE; Sybesma JP; Kuipers JT; Zegers BJ; Borst-Eilers E
Neth J Med; 1976; 19(4-5):201-8. PubMed ID: 980188
[No Abstract] [Full Text] [Related]
40. Immunologic status of children with Hodgkin's disease (HD).
Bogusławska-Jaworska J; Chybicka A; Pisarek J
Arch Immunol Ther Exp (Warsz); 1981; 29(6):725-31. PubMed ID: 6983869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
